#EASD26: Regeneron's antibody helps patients regain muscle after stopping GLP-1 therapy

ConferencepositiveRegeneron investigational antibodyWegovyPositive

AI Analysis

Summary

Regeneron presented mid-stage trial data at EASD26 showing its investigational antibody helped obesity patients regain muscle mass after discontinuing GLP-1 therapy, addressing a known side effect of the drug class.

Clinical Trial Data

Phase

Phase 2

Primary Endpoint

Met

Outcome Details

Regeneron's investigational antibody helped obesity patients regain similar muscle mass to what was lost during GLP-1 therapy after discontinuation

Importance:6/10

Sentiment:

0.70

obesityGLP-1muscle preservationmid-stage trialEASD26antibody

Related Companies

$REGN $NVO

Read the original article

Published by Endpoints News on October 1, 2026 1:42 PM

Read Original